While immune checkpoint CTLA4 or PD-1 blockade therapy, monotherapy or combined, achieved significant survival benefits in patients with metastatic melanoma, a highly immunogenic human tumor [38–40]. The gene discussed is CTLA4; the disease is metastatic melanoma.